Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300

Gene Therapy volume 24, pages 40–48 (2017)Cite this article

Subjects

Abstract

Ras mutations and overexpression of the Ras protein, p21Ras, are main causes of cancer development and progression, which has made the Ras gene and p21Ras important targets for therapy of Ras-driven cancers. We previously prepared recombinant adenovirus KGHV100 based on replication-defective adenovirus type 5, which could intracellularly express anti-p21Ras single chain fragment viable antibodies (scFv) and repress tumor growth in vitro and in vivo. However, the anti-tumor effects of this anti-p21Ras scFv were limited by short-term scFv expression due to a replication defect of KGHV100. To enhance the anti-tumor efficacy and safety of anti-p21Ras scFv, the present study constructed a dual-promoter-regulated recombinant adenovirus KGHV300 that carried anti-p21Ras scFv. In KGHV300, the expression levels of the essential replication genes E1a and E1b, were controlled by the human telomerase reverse transcriptase promoter and the hypoxia response element, respectively, and the anti-p21Ras scFv gene was controlled by the cytomegalovirus promoter. The conditional replication of KGHV300 and its antitumor efficacy were characterized in several tumor cell lines in vitro and in xenograft models of human breast cancer in nude mice. TCID50 assay demonstrated that KGHV300 could replicate in tumor cell lines but not in normal cell lines. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay indicated that the growth of tumor cells was effectively inhibited by KGHV300 infection. In MDA-MB-231 tumor xenograft models, KGHV300 effectively and significantly inhibited tumor growth and induced apoptosis of tumor cells. We concluded that the recombinant adenovirus KGHV300 may be a more potent and safer antitumor therapeutic for Ras-driven cancer biotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Fernandez-Medarde A, Santos E . Ras in cancer and developmental diseases. Genes Cancer 2011; 2: 344–358.

    Article  CAS  Google Scholar 

  2. Adjei AA . Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062–1074.

    Article  CAS  Google Scholar 

  3. Miyakis S, Sourvinos G, Spandidos DA . Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun 1998; 251: 609–612.

    Article  CAS  Google Scholar 

  4. Liu X, Jakubowski M, Hunt JL . KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol 2011; 135: 245–252.

    Article  CAS  Google Scholar 

  5. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR . Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 1995; 55: 1444–1447.

    CAS  PubMed  Google Scholar 

  6. Saki M, Toulany M, Rodemann HP . Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiother Oncol 2013; 108: 473–478.

    Article  CAS  Google Scholar 

  7. Hamdy S, Aprikian A, Begin L, Fair W, Bazinet M . Ras p21 overexpression is a late event in prostate-cancer. Int J Oncol 1994; 4: 627–631.

    CAS  PubMed  Google Scholar 

  8. Gallick GE, Kurzrock R, Kloetzer WS, Arlinghaus RB, Gutterman JU . Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci USA 1985; 82: 1795–1799.

    Article  CAS  Google Scholar 

  9. Novara R, Coda R, Martone T, Vineis P . Exposure to aromatic amines and ras and c-erbB-2 overexpression in bladder cancer. J Occup Environ Med 1996; 38: 390–393.

    Article  CAS  Google Scholar 

  10. Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H et al. Wild-type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL-8 secretion via JAK2 activation. Cell Rep 2015; 12: 511–524.

    Article  CAS  Google Scholar 

  11. Yang JL, Liu DX, Zhen SJ, Zhou YG, Zhang DJ, Yang LY et al. A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues. BMC Cancer 2016; 16: 131.

    Article  Google Scholar 

  12. Yang JL, Pan XY, Zhao WX, Hu QC, Ding F, Feng Q et al. The antitumor efficacy of a novel adenovirus-mediated anti-p21Ras single chain fragment variable antibody on human cancers in vitro and in vivo. Int J Oncol 2016; 48: 1218–1228.

    Article  CAS  Google Scholar 

  13. Shay JW, Wright WE . Telomeres and telomerase: implications for cancer and aging. Radiat Res 2001; 155: 188–193.

    Article  CAS  Google Scholar 

  14. Hsu YH, Lin JJ . Telomere and telomerase as targets for anti-cancer and regeneration therapies. Acta Pharmacol Sin 2005; 26: 513–518.

    Article  CAS  Google Scholar 

  15. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220–224.

    Article  CAS  Google Scholar 

  16. Hewitson KS, Schofield CJ . The HIF pathway as a therapeutic target. Drug Discov Today 2004; 9: 704–711.

    Article  CAS  Google Scholar 

  17. Semenza GL . Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721–732.

    Article  CAS  Google Scholar 

  18. Welsh SJ, Powis G . Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 2003; 3: 391–405.

    Article  CAS  Google Scholar 

  19. Sokkar P, Sathis V, Ramachandran M . Computational modeling on the recognition of the HRE motif by HIF-1: molecular docking and molecular dynamics studies. J Mol Model 2012; 18: 1691–1700.

    Article  CAS  Google Scholar 

  20. Lee KJ, Lee KY, Lee YM . Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1alpha to reverse HRE site in the promoter. Biochim Biophys Acta 2010; 1803: 608–616.

    Article  CAS  Google Scholar 

  21. Su CQ, Sham J, Xue HB, Wang XH, Chua D, Cui ZF et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol 2004; 130: 591–603.

    Article  CAS  Google Scholar 

  22. Post DE, Khuri FR, Simons JW, Van Meir EG . Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933–946.

    Article  CAS  Google Scholar 

  23. Li Y, Idamakanti N, Arroyo T, Thorne S, Reid T, Nichols S et al. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models. Clin Cancer Res 2005; 11: 8845–8855.

    Article  CAS  Google Scholar 

  24. Wirth T, Kuhnel F, Kubicka S . Telomerase-dependent gene therapy. Curr Mol Med 2005; 5: 243–251.

    Article  CAS  Google Scholar 

  25. Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004; 10: 938–949.

    Article  CAS  Google Scholar 

  26. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004; 10: 8603–8612.

    Article  CAS  Google Scholar 

  27. Wang X, Su C, Cao H, Li K, Chen J, Jiang L et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol Cancer Ther 2008; 7: 1598–1603.

    Article  CAS  Google Scholar 

  28. Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005; 7: R220–R228.

    Article  CAS  Google Scholar 

  29. Chen Q, Cui XX, Liang PF, Dou JX, Liu ZY, Sun WW . Immunotherapy with dendritic cells and cytokine-induced killer cells for MDA-MB-231 breast cancer stem cells in nude mice. Am J Transl Res 2016; 8: 2947–2955.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Li W, Miao X, Qi Z, Zeng W, Liang J, Liang Z . Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2. Virol J 2010; 7: 45.

    Article  Google Scholar 

  31. Arango D, Mariadason JM, Wilson AJ, Yang W, Corner GA, Nicholas C et al. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003; 89: 1757–1765.

    Article  CAS  Google Scholar 

  32. Kieback DG . Adenovirus-mediated thymidine kinase gene therapy and coxsackie adenovirus receptor expression in ovarian cancer cells. Cancer Genom Proteom 2008; 5: 311–318.

    CAS  Google Scholar 

  33. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555–1559.

    Article  CAS  Google Scholar 

  34. Kozma SC, Bogaard ME, Buser K, Saurer SM, Bos JL, Groner B et al. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res 1987; 15: 5963–5971.

    Article  CAS  Google Scholar 

  35. Shweta, Mishra KP, Chanda S, Singh SB, Ganju L . A comparative immunological analysis of CoCl2 treated cells with in vitro hypoxic exposure. Biometals 2015; 28: 175–185.

    Article  CAS  Google Scholar 

  36. Shirato K, Kizaki T, Sakurai T, Ogasawara JE, Ishibashi Y, Iijima T et al. Hypoxia-inducible factor-1alpha suppresses the expression of macrophage scavenger receptor 1. Pflugers Arch 2009; 459: 93–103.

    Article  CAS  Google Scholar 

  37. Yamanaka-Tatematsu M, Nakashima A, Fujita N, Shima T, Yoshimori T, Saito S . Autophagy induced by HIF1alpha overexpression supports trophoblast invasion by supplying cellular energy. PLoS One 2013; 8: e76605.

    Article  CAS  Google Scholar 

  38. Dong X, Qu W, Ma S, Zhu Z, Zheng C, He A et al. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo. Cancer Lett 2013; 328: 95–103.

    Article  CAS  Google Scholar 

  39. Brennan AJ, House IG, Oliaro J, Ramsbottom KM, Hagn M, Yagita H et al. A method for detecting intracellular perforin in mouse lymphocytes. J Immunol 2014; 193: 5744–5750.

    Article  CAS  Google Scholar 

  40. Gao H, Liu L, Qu ZY, Wei FX, Wang SQ, Chen G et al. Anti-adenovirus activities of shikonin, a component of Chinese herbal medicine in vitro. Biol Pharm Bull 2011; 34: 197–202.

    Article  CAS  Google Scholar 

  41. Wang HG, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S et al. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994; 9: 2751–2756.

    CAS  PubMed  Google Scholar 

  42. Zhu W, Wei L, Zhang H, Chen J, Qin X . Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo. J Exp Clin Cancer Res 2012; 31: 51.

    Article  CAS  Google Scholar 

  43. Guo J, Gao J, Li Z, Gong Y, Man X, Jin J et al. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo. Cancer Lett 2013; 339: 185–194.

    Article  CAS  Google Scholar 

  44. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004; 10: 162–171.

    Article  CAS  Google Scholar 

  45. Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 2006; 12: 6523–6531.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 81460464) and the Applied Foundation Key Project of Yunnan Province (2013FA059).

Ethical statement

This study received the approval of the Ethics Board of Kunming General Hospital and is also in accordance with the Helsinki Declaration of 1975. Animals involved in the study were cared for in accordance with institutional guidelines.

Author information

Author notes

  1. X Y Pan and X J Liu: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China

    X Y Pan, Q Feng, W X Zhao & J L Yang

  2. Graduate School, Kunming Medical University, Kunming, Yunnan Province, China

    X J Liu, S J Zhen, D X Liu & J L Yang

  3. Department of Genetics, Medical College, Kunming University of Science and Technology, Kunming, Yunnan Province, China

    J Li, Y Luo & J L Yang

  4. Biotechnique College, Southern Medical University, Guangzhou, Guangdong Province, China

    Y L Zhang & H W Li

Authors
  1. X Y Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X J Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S J Zhen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D X Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W X Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y L Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H W Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J L Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to H W Li or J L Yang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pan, X., Liu, X., Li, J. et al. The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300. Gene Ther 24, 40–48 (2017). https://doi.org/10.1038/gt.2016.74

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2016.74

This article is cited by

Search

Advanced search

Quick links